Gao Xiuyan, Chairperson of Junxiu Biotech, recently visited Geistlich Pharma’s headquarters in Switzerland for in-depth discussions with its senior management and representatives responsible for quality, production, and technology. The visit strengthened mutual understanding and trust, laying a solid foundation for continued collaboration between Junxiu Biotech and Geistlich China.
From the signing of the cooperation agreement between Junxiu Biotech and Geistlich China in Yantai in June 2024 to this recent visit to the Swiss headquarters, ongoing exchanges have marked the steady development of the partnership and reflected a shared commitment to regenerative medicine.
Connecting Across Borders Through Shared Values
Geistlich Pharma has extensive expertise in biomaterials for bone, cartilage, and tissue regeneration. Its core values—pioneering regeneration, scientific rigor, family heritage, working together, and a pioneering spirit—underpin its longstanding commitment to the field.
Founded in Yantai in 2012, Junxiu Biotech has dedicated more than a decade to the research, development, manufacturing, and sales of advanced medical devices for regenerative medicine. The company drives product development through research and innovation while maintaining rigorous quality management.
A shared focus on long-term investment, product quality, and evidence-based medicine provides a strong foundation for dialogue and collaboration.
Two Years of Progress and a Deepening Partnership
Since the partnership began, Junxiu Biotech and Geistlich China have maintained close communication, steadily advancing their collaboration through regular exchanges and practical initiatives.
In June 2024, Junxiu Biotech and Geistlich China formally signed a cooperation agreement in Yantai, opening a new chapter in their partnership.
In July 2024, the Geistlich China team visited Junxiu Biotech’s industrial park. A site tour, business discussions, and a friendly basketball game offered opportunities to gain a closer understanding of Junxiu Biotech’s corporate culture and business philosophy.
Over the past two years, senior representatives from Geistlich Pharma have visited Junxiu Biotech on multiple occasions to discuss research and development, production processes, and quality management systems. These face-to-face exchanges have deepened mutual understanding and helped translate shared objectives into action.
Visiting the Swiss Headquarters to Deepen Technical Dialogue
Building on previous visits and exchanges, the trip to Switzerland expanded discussions on quality, production, and technology.
During the visit, Chairperson Gao met with Geistlich Pharma representatives for in-depth discussions on quality management systems, manufacturing processes, and research and development directions. Topics ranged from quality management practices and manufacturing expertise to approaches to R&D, focusing on key aspects of product development and manufacturing.
The visit also offered Junxiu Biotech an opportunity to learn more about an international company’s management practices and technical approaches, establishing further common ground for future professional exchanges and collaboration with Geistlich China.
Moving Forward with a Long-Term Commitment
Lasting partnerships depend on shared values, sustained communication, and practical action. Geistlich Pharma’s commitment to scientific rigor and Junxiu Biotech’s focus on research, innovation, and product quality both reflect a long-term dedication to regenerative medicine.
The visit to Switzerland strengthened mutual understanding and trust, providing a sound foundation for future dialogue and cooperation. Looking ahead, Junxiu Biotech will continue to deepen its partnership with Geistlich China and strengthen professional exchanges. Guided by scientific rigor and a commitment to quality, the two companies will work together to provide better regenerative medicine products and services for clinicians and patients in China.